Bone marrow transplantation. Preliminary results.
DOI:
https://doi.org/10.20344/amp.4480Abstract
From May 1989 to March 1991 60 bone marrow transplants were performed--41 allogeneic and 19 autologous--in patients with malignant and nonmalignant hemopathies and solid tumors. The transplant related mortality was 19.4% and 10.5% for allografts and autografts, respectively. The projected relapse free survival at 22 months in patients with malignant hemopathies who underwent allotransplantation in early phase was 81% and, in patients in advanced phase 21.4% (p less than 0.001). In patients with aplastic anemia the actuarial survival at 22 months is 60%. In autografted patients, only one failed to have full engraftment and is dependent on platelet support at day 79. Follow-up in all autografts is less than one year. These preliminary results of our bone marrow transplant program show low morbidity and mortality related to transplantation and suggest significant therapeutic effect.Downloads
Downloads
How to Cite
Issue
Section
License
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.